LONDON - Versarien Plc (AIM: VRS), a company specializing in advanced engineering materials, has announced a distribution agreement to market a new graphene-based biosensor chip technology across the UK and Europe. The biosensors, developed by South Korea's A Barristor Company (ABC), incorporate a novel barristor sensor platform that significantly amplifies current modulation, a breakthrough that could enhance medical diagnostics.
The graphene barristor devices, which employ a Schottky barrier between graphene and silicon, offer over 10,000 times the current modulation of traditional graphene field-effect transistors (GFETs). This advancement addresses many of the limitations faced by GFETs. The sensors will be available either as individual chips or on a wafer scale, with the graphene surface finished with pyrenebutanoic acid succinimidyl ester (PBASE) or a linker chosen by the customer.
Versarien's CEO, Dr. Stephen Hodge, expressed enthusiasm for the partnership with ABC, highlighting the potential impact of the biosensor platform on medical diagnostics. Dr. Hodge, who has previously collaborated with ABC's CEO, Prof. Hyun-Jong Chung, anticipates that this agreement will leverage the intellectual property licensed to MCK Tech Co. Ltd., another South Korean company responsible for supplying the chemical vapor deposition (CVD) grown graphene used in the devices.
The distribution deal could expand to include a broader range of sensor products based on ABC's ongoing developments, potentially encompassing infrared detection, gas/chemical detection, temperature sensing, and multi-sensor chip technologies.
This strategic move allows Versarien to capitalize on its licensed technology and reinforces its commitment to advancing material applications in the biosensor market. The information for this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.